As reported in my November 30th, 2012 post, the U.S. Supreme
Court granted certiorari to review the issue "are human genes
patentable?" The issue arises from the long-running dispute
among a consortium of plaintiffs, led by the American Civil
Liberties Union (collectively "ACLU") who sued Myriad
Genetics, Inc. and the Directors of the University of of Utah
Research Foundation (collectively "Myriad") challenging
the patentability of composition and method claims related to human
genetics. The Supreme Court's opinion has the potential to
overrule over 30 years USPTO practice that supported the growth of
the U.S. biotechnology industry.
The Appealed Patent Claims
The case started when the ACLU sought a declaration that 15
claims from seven patents assigned to Myriad were drawn to
patent-ineligible subject matter under 35 U.S.C. section 101. The
challenged composition claims cover two isolated human genes, BRCA1
and BRCA2 (collectively "BRACA1/2″ or "BRCA")
and